Lyka Labs Limited (LYKALABS) AI Stock Analysis

Lyka Labs Limited

(NSE:LYKALABS)

Select Model

Rating:54Neutral

Price Target:INR 84.00▲(11.90% Upside)

Action:reiterated

Date:08/26/26

Mixed financial performance is the dominant factor, with balance sheet gains tempered by revenue and cash flow volatility. Bullish technical indicators provide moderate support, while negative P/E weighs on valuation.

Positive Factors

Balance-sheet deleveragingDebt has fallen substantially from 2023 to 2026 while equity remains positive, reducing balance-sheet pressure and improving financial flexibility. This repair can lower funding risk and leave more capacity to support pharmaceutical operations through the next several quarters.

Negative Factors

Revenue and earnings deteriorationThe latest reversal from growth and profit to lower revenue and a substantial net loss indicates that earnings quality and cost control remain unstable. If this pattern persists, it can weaken reinvestment capacity, constrain operational flexibility, and undermine confidence in durable profitability.

Lyka Labs Limited (LYKALABS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 2.77B
Dividend Yield: ―
Average Volume (3M): 5,243
Price to Earnings (P/E): -30.6
Beta (1Y): 1.45
Revenue Growth: 6.10%
EPS Growth: -309.17%
Country: India
Employees: 648
Sector: General
Sector Strength: 55
Industry: Biotechnology

Lyka Labs Limited Business Overview & Revenue Model

Company Description

Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (API...

How the Company Makes Money

Lyka Labs Limited makes money primarily through revenue earned from the sale of its pharmaceutical products. Key revenue streams typically include (1) domestic sales of finished dosage formulations sold to distributors, hospitals, pharmacies, and oth...

Lyka Labs Limited Financial Statement Overview

Summary

Mixed profile with volatile revenue, inconsistent profitability, and weak cash flows offset by strengthened balance sheet via debt reduction and equity growth.

Income Statement

35Negative

Balance Sheet

75Positive

Cash Flow

40Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	1.38B	1.28B	1.41B	1.05B	916.90M	1.84B
Gross Profit	311.71M	279.37M	851.35M	599.41M	152.84M	1.30B
EBITDA	-5.41M	-36.57M	201.67M	167.59M	128.47M	1.01B
Net Income	-88.99M	-100.32M	80.12M	-24.89M	-132.12M	390.00M
Balance Sheet
Total Assets	0	1.75B	1.76B	1.57B	1.52B	1.86B
Cash, Cash Equivalents and Short-Term Investments	18.93M	13.85M	13.63M	62.91M	119.39M	170.59M
Total Debt	0	488.69M	391.84M	586.50M	751.02M	1.30B
Total Liabilities	-908.31M	837.05M	726.24M	884.59M	1.06B	1.72B
Stockholders Equity	908.31M	923.93M	1.04B	681.54M	454.41M	133.38M
Cash Flow
Free Cash Flow	51.46M	-75.25M	-137.55M	-74.58M	7.67M	717.33M
Operating Cash Flow	136.84M	36.06M	18.99M	17.73M	89.53M	792.46M
Investing Cash Flow	-46.95M	-111.03M	-117.96M	-94.88M	73.50M	-61.72M
Financing Cash Flow	-91.69M	75.12M	52.92M	19.53M	-216.43M	-631.77M

Lyka Labs Limited Technical Analysis

Technical Analysis SentimentNeutral

Last Price75.07

Price Trends

50DMA79.73Negative

100DMA74.07Positive

200DMA68.42Positive

Market Momentum

MACD-0.03Positive

RSI42.69Neutral

STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Neutral. The current price of 75.07 is below the 20-day moving average (MA) of 79.68, below the 50-day MA of 79.73, and above the 200-day MA of 68.42, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.69 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LYKALABS.

Lyka Labs Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:LYKALABS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SUPRIYA	67Neutral	INR 68.10B	34.37	―	0.12%	28.14%	11.38%
IN:ZOTA	59Neutral	INR 40.31B	-39.62	―	0.08%	68.95%	-55.82%
IN:DCAL	56Neutral	INR 22.76B	33.34	―	―	-20.86%	-34.51%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:LYKALABS	54Neutral	INR 2.78B	-30.64	―	―	6.10%	-309.17%
IN:HALEOSLABS	47Neutral	INR 4.11B	26.68	―	0.11%	-3.12%	-8.49%
IN:PANACEABIO	47Neutral	INR 19.17B	-270.04	―	―	10.26%	-162.02%

* General Sector Average

Performance Comparison

IN:LYKALABS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:LYKALABS	Lyka Labs Limited	77.00	-17.72	-18.71%
IN:DCAL	Dishman Carbogen Amcis Ltd.	145.15	-146.50	-50.23%
IN:PANACEABIO	Panacea Biotec Limited	312.95	-119.10	-27.57%
IN:HALEOSLABS	SMS Lifesciences India Ltd.	1359.20	148.39	12.26%
IN:SUPRIYA	Supriya Lifescience Limited	846.20	62.38	7.96%
IN:ZOTA	Zota Health Care Ltd.	1328.80	-244.92	-15.56%

Lyka Labs Limited Corporate Events

Lyka Labs Files SEBI Dematerialisation Compliance Certificate for September Quarter

Oct 8, 2026

Lyka Labs Limited has submitted to the stock exchanges a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026. The company forwarded a certificate from its...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 26, 2026

Lyka Labs Limited AI Stock Analysis